137 related articles for article (PubMed ID: 21881300)
1. [Drug discovery by formulation design and innovative drug delivery systems (DDS)].
Okada H
Yakugaku Zasshi; 2011; 131(9):1271-87. PubMed ID: 21881300
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002.
Uchida T; Kanazawa T; Kawai M; Takashima Y; Okada H
J Pharmacol Exp Ther; 2011 Aug; 338(2):443-50. PubMed ID: 21531792
[TBL] [Abstract][Full Text] [Related]
3. Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002.
Uchida T; Kanazawa T; Takashima Y; Okada H
Chem Pharm Bull (Tokyo); 2011; 59(2):196-201. PubMed ID: 21297299
[TBL] [Abstract][Full Text] [Related]
4. Transdermal anti-nuclear kappaB siRNA therapy for atopic dermatitis using a combination of two kinds of functional oligopeptide.
Ibaraki H; Kanazawa T; Takashima Y; Okada H; Seta Y
Int J Pharm; 2018 May; 542(1-2):213-220. PubMed ID: 29551748
[TBL] [Abstract][Full Text] [Related]
5. Development of a Liquid Crystal Formulation that Can Penetrate the Stratum Corneum for Intradermal Delivery of Small Interfering RNA.
Kawai M; Ibaraki H; Takashima Y; Kanazawa T; Okada H
Mol Pharm; 2021 Mar; 18(3):1038-1047. PubMed ID: 33395310
[TBL] [Abstract][Full Text] [Related]
6. [Once-a-month injectable microcapsules of leuprorelin acetate].
Toguchi H; Ogawa Y; Okada H; Yamamoto M
Yakugaku Zasshi; 1991 Aug; 111(8):397-409. PubMed ID: 1795229
[TBL] [Abstract][Full Text] [Related]
7. Anti-RelA siRNA-Encapsulated Flexible Liposome with Tight Junction-Opening Peptide as a Non-invasive Topical Therapeutic for Atopic Dermatitis.
Ibaraki H; Kanazawa T; Kurano T; Oogi C; Takashima Y; Seta Y
Biol Pharm Bull; 2019; 42(7):1216-1225. PubMed ID: 31257297
[TBL] [Abstract][Full Text] [Related]
8. [Design and development of controlled release of drugs from injectable microcapsules].
Takada S; Ogawa Y
Nihon Rinsho; 1998 Mar; 56(3):675-9. PubMed ID: 9549355
[TBL] [Abstract][Full Text] [Related]
9. Development of an Innovative Intradermal siRNA Delivery System Using a Combination of a Functional Stearylated Cytoplasm-Responsive Peptide and a Tight Junction-Opening Peptide.
Ibaraki H; Kanazawa T; Takashima Y; Okada H; Seta Y
Molecules; 2016 Sep; 21(10):. PubMed ID: 27669207
[TBL] [Abstract][Full Text] [Related]
10. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.
Okada H; Heya T; Ogawa Y; Shimamoto T
J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294
[TBL] [Abstract][Full Text] [Related]
11. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate.
Okada H
Adv Drug Deliv Rev; 1997 Oct; 28(1):43-70. PubMed ID: 10837564
[TBL] [Abstract][Full Text] [Related]
12. Intracellular delivery of siRNA by cell-penetrating peptides modified with cationic oligopeptides.
Ishihara T; Goto M; Kodera K; Kanazawa H; Murakami Y; Mizushima Y; Higaki M
Drug Deliv; 2009 Apr; 16(3):153-9. PubMed ID: 19514975
[TBL] [Abstract][Full Text] [Related]
13. Microencapsulation of protein drugs for drug delivery: strategy, preparation, and applications.
Ma G
J Control Release; 2014 Nov; 193():324-40. PubMed ID: 25218676
[TBL] [Abstract][Full Text] [Related]
14. [Strategy and collaboration between medicinal chemists and pharmaceutical scientists for drug delivery systems].
Mano T
Yakugaku Zasshi; 2013; 133(1):67-72. PubMed ID: 23292022
[TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of small interfering RNA targeting nuclear factor κB in mice with collagen-induced arthritis using arginine-histidine-cysteine based oligopeptide-modified polymer nanomicelles.
Kanazawa T; Endo T; Arima N; Ibaraki H; Takashima Y; Seta Y
Int J Pharm; 2016 Dec; 515(1-2):315-323. PubMed ID: 27765724
[TBL] [Abstract][Full Text] [Related]
16. Formulation, optimization and characterization of cationic polymeric nanoparticles of mast cell stabilizing agent using the Box-Behnken experimental design.
Gajra B; Patel RR; Dalwadi C
Drug Dev Ind Pharm; 2016; 42(5):747-57. PubMed ID: 26559522
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
[TBL] [Abstract][Full Text] [Related]
18. [Design of nanohydrogel-incorporated microcapsules for appropriate controlled-release of peptide drugs].
Ichikawa H; Fukumori Y
Yakugaku Zasshi; 2007 May; 127(5):813-23. PubMed ID: 17473523
[TBL] [Abstract][Full Text] [Related]
19. [Regulatory authorities expect innovative drug delivery systems (DDS)].
Mori K
Yakugaku Zasshi; 2013; 133(1):73-80. PubMed ID: 23292023
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic applications of click chemistry for pharmaceutical drug discovery and drug delivery.
Meghani NM; Amin HH; Lee BJ
Drug Discov Today; 2017 Nov; 22(11):1604-1619. PubMed ID: 28754291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
